Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

A judge formally approved a plan Friday to turn OxyContin maker Purdue Pharma into a new company no longer owned by members of the Sackler family and with its profits going to fight the opioid epidemic.

U.S. Bankruptcy Judge Robert Drain officially confirmed the reorganization Friday, more than two weeks after he announced he would do so pending two largely technical changes to the plan presented by the company and hashed out with lawyers representing those with claims against the company.

His confirmation took more than six hours to read in court earlier this month, and the written version is 159 pages long, full of reasoning that appeals courts can consider later. Several states among other parties have already appealed the decision.

Story continues below advertisement

The deal resolves some 3,000 lawsuits filed by state and local governments, Native American tribes, unions, hospitals and others who claimed the company’s marketing of prescription opioids helped spark and continue an overdose epidemic linked to more than 500,000 deaths in the U.S. in the last two decades.

The plan will use company profits and $4.5-billion in cash and charitable assets from members of the Sackler family to pay some individual victims amounts expected to range from $3,500 to $48,000, and help fund opioid treatment and prevention programs across the U.S.

Members of the Sackler family are also required to get out of the opioid business worldwide in time.

Millions of company documents, including communications with company lawyers, are to be made public.

The changes are to take effect when the bankruptcy process is finalized; the earliest that could be is in December.

The attorneys generals from the states of Connecticut, Maryland, Washington and the District of Columbia, as well as the U.S. Bankruptcy Trustee have all announced appeals. Their chief objection is that members of the wealthy Sackler family would be granted protection from lawsuits over opioids.

For many people in recovery from opioid addictions or who have lost loved ones to overdoses, the deal is infuriating.

Story continues below advertisement

Ellen Isaacs, a mother whose son died from an overdose, filed court papers requesting Drain not accept the plan. At a hearing on Monday, she gave a passionate some sometimes tearful 40-minute speech on her request. Like other activists, she asserted that Sackler family members – who have never been charged with criminal wrongdoing – are getting away with crimes, and that politicians and courts are not doing enough to end the opioid epidemic.

“The attorneys are playing games on paper and humans are dying,” she said.

Drain said the money from the settlement would help avert more deaths, even if it will come too late for Isaacs’ son.

“I did not become a judge to get things wrong,” he told her.

He stood by his confirmation of the plan.

At the hearing, Drain also said he would approve a request from Purdue to use nearly $7-million to start setting up the funds that will distribute settlement money to victims, government entities and others. He also, for the third year, approved a plan of incentive payments for Purdue executives if they meet certain goals.

Story continues below advertisement

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies